Key facts
- This page summarizes Michael P. Rutz's Form 4 filing for Sotera Health Co (SHC).
- 1 reported transaction and 5 derivative rows are listed below.
- Accepted by SEC: 26 Aug 2025, 18:08.
Michael P. Rutz - 22 Aug 2025 Form 4 Insider Report for Sotera Health Co (SHC)
- Reporting relationship
- President of Sterigenics
- Issuer ticker
- SHC
- Reported as of
- 22 Aug 2025
- Net transaction value
- -$2,074,306
- SEC form
- 4
- Accepted by SEC
- 26 Aug 2025, 18:08:01 UTC
- Prior SEC filing
- 04 Mar 2025
- Next SEC filing
- 04 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- Matthew J. Klaben, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael P. Rutz filed Form 4 for Sotera Health Co (SHC) on 26 Aug 2025.
Change
- Previous filing in this sequence was filed on 04 Mar 2025.
- Current net transaction value: -$2,074,306.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001599220
Primary reporting owner
Rutz Michael P
- Relationship
- President of Sterigenics
- Address
- C/O SOTERA HEALTH COMPANY, 9100 SOUTH HILLS BLVD, SUITE 300, BROADVIEW HEIGHTS
- Signature
- Matthew J. Klaben, Attorney-in-Fact
- Signature date
- 26 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SHC
transaction
Common Stock
Sale
- Transaction value
- $2,074,306
- Shares
- -126,611
- Change %
- -22%
- Price
- $16.38
- Shares after
- 450,204
- Date
- 22 Aug 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SHC
holding
Derivative
Stock Options
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 68,063
- Date
- 22 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 68,063
- Exercise price
- $14.59
- Footnotes
- F3, F4
SHC
holding
Derivative
Stock Options
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 53,879
- Date
- 22 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 53,879
- Exercise price
- $17.59
- Footnotes
- F3, F5
SHC
holding
Derivative
Stock Options
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 63,857
- Date
- 22 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 63,857
- Exercise price
- $20.03
- Footnotes
- F3, F6
SHC
holding
Derivative
Stock Options
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 111,801
- Date
- 22 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 111,801
- Exercise price
- $23.00
- Footnotes
- F3, F7
SHC
holding
Derivative
Performance RSUs
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 24,289
- Date
- 22 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,289
- Exercise price
- Footnotes
- F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $16.30 - $16.54. The reporting person hereby undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F2
These securities consist of 80,901 RSUs and 369,303 shares of Common Stock.
Footnote F3
No transaction is being reported on this line. Reported on a previously filed Form 4.
Footnote F4
These options were granted on March 4, 2024, pursuant to the terms of a stock option agreement under the 2020 Incentive Plan. The options vest annually in three equal installments commencing March 2, 2025, subject to vesting conditions.
Footnote F5
These options were granted on March 6, 2023, pursuant to the terms of a stock option agreement under the 2020 Incentive Plan. The options vest in annually in three equal installments commencing March 2, 2024, subject to the Reporting Person's continued service through each such date..
Footnote F6
These options were granted on March 2, 2022, pursuant to the terms of a stock option agreement under the 2020 Incentive Plan. The options vest in three equal installments on each of the first three anniversaries of the date of grant, subject to the Reporting Person's continued service thourgh each such date.
Footnote F7
These options were granted on November 20, 2020, pursuant to the terms of a stock option agreement under the 2020 Incentive Plan. The options vest in four equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service through each such date.
Footnote F8
These securities consist of a maximum number of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each additional RSU represents the Reporting Person's right to receive one share of Common Stock, subject to stock price-related performance conditions. The additional RSUs generally vest annually in 60%, 20%, and 20% installments, respectively, commencing March 3, 2026, subject to performance.
SEC remarks
The Power of Attorney for Mr. Rutz is filed as an exhibit to the Form 3 filed on November 20, 2020, which is hereby incorporated by reference.